Reply  by Laurila, Katariina & Lepäntalo, Mauri
Regarding “Adjuvant arteriovenous fistula as a means
of rescue for infrapopliteal venous bypass with poor
runoff ”
Laurila et al1 have noted the lack of impact of creating an
adjuvant distal arteriovenous fistula (dAVF) on patency and limb
salvage rates despite improved graft flow. In their study, the graft
material was autologous saphenous vein (ASV) and was anasto-
mosed to crural outflow sites in 19 patients (25%) and pedal
arteries in 58 (75%). In a prior publication, these authors2 pre-
sented similar conclusions where adjuvant fistulas were constructed
with polytetrafluoroethylene (PTFE) bypasses.
The theoretic basis for using distal arteriovenous fistulas as
adjuncts to crural reconstruction to maintain graft patency and
distal perfusion is based on the need to reduce the vascular
overload being presented to the distal circuit and, at the same
time, to keep graft flow above the critical thrombotic threshold
level. Establishing such a vent results in increased flow in the
graft, much of which is directed into the high capacitance
venous circulation. The amount of blood that can be accepted
by the arterial runoff, albeit limited, will perfuse distally and
reverse the ischemic state.
We have been impressed by the minimal increment of blood
required to effect this change. Intraoperative flow studies have
demonstrated a trebling of graft flow with an adequate dAVF. The
predominant flow is through the fistula, but arterial flows of 60
mL/min have been maintained and have resulted in limb salvage.
The differences in outcomes between our cases and those of
Laurila et al1 are based on a number of parameters, some obvious
and others speculative. There is a major difference to be expected
in outcomes based on the use of PTFE, ASV, or umbilical vein
graft (UV) as the conduit material. We have repetitively empha-
sized the negative impact of PTFE in that this noncompliant
material is generally unable to provide sufficient incremental distal
flow, unless hemodynamic revisions are initiated as described by
Ascer et al.3
Use of ASV, on the other hand, can maintain continuous
flow even with a low thrombotic threshold velocity, enabling
improved likelihood for patency in adverse circumstances even
in the absence of an adjunctive fistula. We have deployed
adjunctive fistulas with ASV in 47 cases and concur with the
findings of Laurila et al.1 Nonetheless, we were able in several
instances to clearly document the conversion of certain failure
to durable patency and success. Perhaps there are other factors
at work, and these include the documentation of venous out-
flow quality, surgical technique for creating the dAVF, and the
requirement for at least some arterial runoff. We have previously
addressed all these factors.4-6
In our view, an adjunctive fistula does enable improved pa-
tency in addition to increased graft flow under conditions where a
prosthetic is required that is compliant (UV in our experience),
where the outflow tract is strictly at the crural level, and where
there is strict adherence to specific surgical technique including
four-quadrant interrupted sutures and tourniquet control. We
continue to believe that the creation of a dAVF as an adjunct to
prosthetic bypass at the crural level has validity and the potential for
significantly improving crural limb salvage rates and return to a
functional and pain-free existence.
It is unlikely that randomized prospective studies will ever be
performed to define the “truth”; we therefore bear the responsi-
bility of defining the parameters in which we perform our opera-
tions. Superficial similarities fade under scrutiny that discloses
differences in methods and materials. Clearly a UV-peroneal by-
pass plus dAVF cannot be equated with an ASV-dorslis pedis
bypass plus dAVF.
I congratulate the authors for their work and inciteful findings
and hope that they continue to expand their observations.
Dr. Herbert Dardik, MD
Chief of General/Vascular Surgery
Englewood Hospital and Medical Center
Englewood, NJ
Clinical Professor of Surgery
Mt Sinai School of Medicine
New York, NY
University of Pennsylvania
Philadelphia, PA
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Reply
We thankDrDardik for his continued interest in our work and
for his letter highlighting the differences in the feasibility of adju-
vant arteriovenous fistulas in combination with different types of
graft materials. It is true that vein grafts may stay patent despite
very low flow, and therefore, indeed, there may also be other
factors affecting patency.
We were happy with our results until we compared our results
with matched controls. In our previous study of polytetrafluoro-
ethylene (PTFE) bypass, vein cuff, and adjuvant arteriovenous
fistula, there was no benefit in patency from the fistula in a
prosthetic bypass either.1 Because our studies focus on bypasses
with PTFE and vein grafts, we cannot comment the use of an
adjuvant arteriovenous fistula with umbilical vein grafts.
Dr Dardik has large experience with these grafts,2,3 and cer-
tainly, different graft materials differ in compliance and therefore
also in patency. Our results have, however, affected our clinical
practice, and currently, an arteriovenous fistula combined with a
bypass is used only in exceptional situations.
Katariina Laurila, MD
Mauri Lepäntalo, MD
Vascular Surgery
Helsinki University Central Hospital
Helsinki, Finland
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Error in Charing Cross Venous Ulcer Questionnaire
(CXVUQ)
We have encountered an unexpected problem with the Char-
ing Cross Venous Ulcer Questionnaire (CXVUQ), an ulcer-
specific quality-of-life instrument previously reported in this jour-
nal.1 When designing the Honey as Adjuvant Leg ulcer Therapy
(HALT) Trial (ISRCTN06161544), the CXVUQ appeared to be
a promising tool that would complement the more generic Short
Form-36 (SF-36).
When we analyzed the data, however, two domains (cosmesis
and emotional status) scored considerably higher than the other
domains (Table), which seemed incongruent with the scoring of
CXVUQ. Low scores on the CXVUQ indicate better quality-of-
life outcomes. We therefore investigated the scores of all those
participants with healed and unhealed ulcers at end point. The
CXVUQ should have discriminated between those that did heal
and those that did not, irrespective of treatment. Participants with
healed ulcers should have scored lower (ie, better) than those with
unhealed ulcers at end point. However, the opposite was true for
cosmesis and emotional status.
This problem seems to have been created by an error in the
original publication. Questions three and seven were incorrectly
scaled and thus the best answers score highest instead of lowest.
When we recoded the data so that the best answers gave the lowest
scores, the data were more congruent and participants with healed
ulcers did indeed score lower than those with unhealed ulcers.
Another research group using the CXVUQ has independently
arrived at the same solution (Irene Wong and David Thompson,
personal communication),2 and we have since been able to confirm
the error from a second publication by the instrument’s authors.3
This publication is not listed inMedline or CINAHL, and will only
come to user’s attention if they search EMBASE or SCOPUS.
The CXVUQ is a disease-specific instrument that has excellent
potential for use in clinical trials. It appears to have discriminant
characteristics,4 unlike the Hyland scale.5 However, future users
should be aware of the problem we have outlined and its solution.
Andrew Jull, MA(Appl)
Varsha Parag, MSc
Clinical Trials Research Unit
University of Auckland
Auckland, New Zealand
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Table. Mean domain scores for healed and unhealed cohorts using uncorrected and corrected variables
Domain
Uncorrected results* Corrected results*
Healed Unhealed Healed Unhealed
Social interaction 25.7  11.1 37.6  16.1 24.9  12.2 38.3  17.4
Domestic activities 24.9  11.6 33.9  18.0 23.8  12.9 34.9  19.8
Cosmesis 83.6  11.5 72.7  14.8 30.8  14.8 44.4  18.5
Emotional status 78.2  15.5 65.4  18.7 34.0  17.9 49.6  21.8
*Data presented as mean  standard deviation.
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